Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)
China · Delayed Price · Currency is CNY 50.15
-0.31 (-0.61%)
Jan 27, 2026, 3:04 PM CST
SHE:002653 Revenue
Haisco Pharmaceutical Group had revenue of 1.30B CNY in the quarter ending September 30, 2025, with 22.05% growth. This brings the company's revenue in the last twelve months to 4.27B, up 14.72% year-over-year. In the year 2024, Haisco Pharmaceutical Group had annual revenue of 3.72B with 10.92% growth.
Revenue (ttm)
4.27B
Revenue Growth
+14.72%
P/S Ratio
13.03
Revenue / Employee
800.12K
Employees
5,337
Market Cap
55.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.72B | 366.28M | 10.92% |
| Dec 31, 2023 | 3.36B | 339.78M | 11.27% |
| Jan 1, 2023 | 3.02B | 241.98M | 8.73% |
| Jan 1, 2022 | 2.77B | -556.28M | -16.71% |
| Dec 31, 2020 | 3.33B | -607.74M | -15.44% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharmaron Beijing | 13.54B |
| Chongqing Zhifei Biological Products | 10.91B |
| Shanghai RAAS Blood Products | 7.95B |
| Beijing Tiantan Biological Products | 6.42B |
| Asymchem Laboratories (Tianjin) | 6.29B |
| Shanghai Allist Pharmaceuticals | 4.76B |
| Hualan Biological Engineering | 4.27B |
| Xiamen Amoytop Biotech | 3.34B |